Nascent Biotech is a California-based company focused on the development and delivery of human antibodies and cytokine responses for the treatment of cancer.
The innate ability of the intelligence of the natural human immune system to generate a cancer specific response combined with Nascent Biotech’s technical skills opens the door for immunologically based therapeutics for human cancer.
Nascent Biotech is using and developing human antibodies and cytokine responses obtained from the innate natural human immune response as a drug discovery platform for identifying new antibodies and antigens for commercialization.
Our insight into the natural human immune response defines important targets for therapeutic intervention thus enabling the rapid development of new classes of safe, non-toxic, and specific biological drugs for use in the clinic.
The company’s technology portfolio is based upon the natural human immune system, uniquely utilizing the immune system’s innate capabilities and selectivity to produce effective immune boosting and regulation biomolecules.
In our bodies, the natural immune response to harmful agents is both oligoclonal and oligocelluar; that is, several different antibodies and cell types are generated to attach a particular disease agent.
Use of a single monoclonal antibody (mAB), or monotherapy, to treat a disease – the approach employed by most pharmaceutical / biotechnology companies – may not be optimal and is certainly not the preferred natural approach.
Nascent Biotech’s approach to treatment of disease is to “mimic” the body’s natural antibody and cellular reponses by identifying and combining antibodies and natural cytokines into a single therapy for more effective disease treatment.
Nascent Biotech believes that by combining specifically selected biomolecules into a potent “cocktail”, one can create an efficient, multi-targetted attack against disease. Applications of this technology span cancer, metabolic disorders and infectious disease indications.
Nascent Biotech’s lead product, Pritumumab, a natural human antibody.
Pritumumab is a fully natural human IgG antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer.
The recognized target is ecto-domain vimentin that is expressed on the cell surface of a variety of adenocarcinomas, including brain cancers and melanoma, but not expressed by normal tissues and cells.
Nascent Biotech has been awarded 4 patents on CLNH5 from the United States Patent Office: 4618577; 6051229; 6051387; 6090924.
MultiPharm™ is a platform technology proprietary to Nascent Biotech that may have additive and synergistic effects not only for cancer therapy but also diabetes, autoimmunity, and transplantation.
MultiPharm™ uses multiple agents (antibodies and/or cytokines).
CHIEF EXECUTIVE OFFICER
Sean Carrick brings to Nascent an extensive track record of success with a career that spans more than 30 years of building and leading successful Life Science Companies in large, mid-cap and venture-backed stages. In addition, Mr. Carrick holds a BS Degree in Economics and Business Administration from Duquesne University and has completed several strategic leadership programs.
BRANDON J. PRICE, PHD
SENIOR VICE PRESIDENT, BUSINESS DEVELOPMENT
Dr. Price has more than 30 years in the biopharmaceutical industry. Recently he co-founded Biogenin, a Mexican company that licenses, develops and registers human and veterinary products (pharmaceuticals, diagnostics and medical devices) for Latin American markets. Dr. Price has been CEO of four biotechnology start-ups (plant transgenic expression systems, stem cell therapies, chemical cancer drugs, synthetic vaccines), and has held senior management positions at Cardinal Health and Ortho Diagnostic Systems (a Johnson & Johnson company). In addition, he co-founded the Institute for Cell Analysis at the University of Miami (FL), and the International Center for Entrepreneurial Excellence at the University of Guadalajara. He has served as Board Chair of the Virginia Biotechnology Association, Maryland’s counterpart, MdBIO, and was named 2001 Biotechnology Leader of the Year in Virginia. He currently sits on the Boards of four companies, and chairs the Advisory Board for the Professional Science Management Program in Bioinformatics at Virginia Commonwealth University (Richmond, VA). Presently, he is Visiting Professor at the University of Guadalajara School of Business where he teaches the course “Entrepreneurism and Business Planning”. He holds the B.S. and Ph.D. degrees in Biophysics from the University of Michigan in Ann Arbor and is the author of more than 50 articles in the scientific and business literature.
CHIEF FINANCIAL OFFICER
Lowell Holden has been the CFO and Chief Accounting Officer of the Company since May 2014. Since 1983, Mr. Holden has owned and operated his own consulting firm, LS Enterprises, Inc., which provides business consulting, accounting and other services to businesses. Mr. Holden has a broad range of business experience including managing, securing financing, structuring of transactions, and is experienced and knowledgeable in managing relationships with customers, financing institutions and stockholders. Mr. Holden also has a background in assisting companies in fulfilling their financial auditing and SEC reporting requirements. Mr. Lowell Holden has a Bachelor’s of Science degree from Iowa State University.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty eight hundred dollars for Nascent Biotech, Inc. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Nascent Biotech, Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.